Federico Gardini

Bio3 Research SRL is engaged in the research, identification and development of novel therapeutic agents, specializing in the biotechnology, bioelectronics, and biomedicine fields. The firm develops proprietary compounds that serve as inhibitors in diseases related to High Mobility Group Box 1 (HMGB1) protein over-expression and biological properties. It monitors the effect of developed and patented biological agents on cardiovascular disorders, renal disorders, and connective tissue regeneration, such as cartilage repair, wound healing, and bone matrix regeneration. It collaborates with biopharmaceutical companies, academies, and scientists, with focus on intellectual property transfer, patent registration, and commercialization of novel products in the pharmaceutical marketplace. The company was founded by Francesco Paolo Pilato in 2001 and is headquartered in Milan, Italy.